ストックスクリーナーアプリを入手
54.32
2.84%
1.50
アフターアワーズ：
54.38
0.06
+0.11%
前日終値:
$52.82
開ける：
$52.81
24時間の取引高:
1.72M
Relative Volume:
0.54
時価総額：
$4.94B
収益：
$170.10M
当期純損益:
$-239.59M
株価収益率:
-19.40
EPS:
-2.8
ネットキャッシュフロー:
$-191.20M
1週間 パフォーマンス:
-9.06%
1か月 パフォーマンス:
-17.61%
6か月 パフォーマンス:
+13.38%
1年 パフォーマンス:
+14.36%
1日の値動き範囲:
$52.60
$55.08
1週間の範囲:
$51.80
$59.46
52週間の値動き範囲:
$30.04
$71.13
Crispr Therapeutics Ag Stock (CRSP) Company Profile
CRSP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
54.32 | 5.24B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-14 | アップグレード | Evercore ISI | In-line → Outperform |
| 2025-02-12 | アップグレード | TD Cowen | Sell → Hold |
| 2025-02-03 | 開始されました | H.C. Wainwright | Buy |
| 2024-08-06 | 繰り返されました | Needham | Buy |
| 2024-08-02 | 開始されました | Rodman & Renshaw | Buy |
| 2024-06-28 | 再開されました | Guggenheim | Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-11 | ダウングレード | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | 開始されました | Mizuho | Buy |
| 2023-08-17 | アップグレード | Citigroup | Neutral → Buy |
| 2023-05-30 | 開始されました | William Blair | Outperform |
| 2023-04-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2023-03-17 | 開始されました | Bryan Garnier | Buy |
| 2023-03-07 | 開始されました | Robert W. Baird | Neutral |
| 2022-10-11 | 開始されました | Morgan Stanley | Underweight |
| 2022-08-09 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2022-06-23 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-06-17 | 開始されました | BMO Capital Markets | Outperform |
| 2022-04-28 | 開始されました | Credit Suisse | Neutral |
| 2021-12-07 | 開始されました | Cowen | Market Perform |
| 2021-10-19 | 開始されました | SVB Leerink | Outperform |
| 2021-06-14 | アップグレード | Citigroup | Sell → Neutral |
| 2021-04-21 | アップグレード | Jefferies | Hold → Buy |
| 2021-03-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-12-10 | 繰り返されました | Chardan Capital Markets | Buy |
| 2020-12-10 | ダウングレード | Jefferies | Buy → Hold |
| 2020-12-10 | 繰り返されました | Needham | Buy |
| 2020-12-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | 開始されました | BofA Securities | Buy |
| 2020-07-28 | 繰り返されました | Needham | Buy |
| 2020-07-14 | 開始されました | SunTrust | Buy |
| 2020-06-15 | 繰り返されました | Canaccord Genuity | Buy |
| 2020-03-05 | 開始されました | Stifel | Hold |
| 2020-02-03 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-11-19 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-08-01 | 開始されました | Jefferies | Buy |
| 2019-07-26 | 開始されました | Canaccord Genuity | Buy |
| 2019-06-10 | 開始されました | ROTH Capital | Buy |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-14 | 開始されました | William Blair | Mkt Perform |
| 2019-01-28 | ダウングレード | Goldman | Buy → Neutral |
| 2019-01-22 | ダウングレード | Citigroup | Neutral → Sell |
すべてを表示
Crispr Therapeutics Ag (CRSP) 最新ニュース
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know - MSN
Watch for Trend Continuation in CRISPR Therapeutics AG Next WeekJuly 2025 Rallies & Free AI Powered Buy and Sell Recommendations - thegnnews.com
Vestmark Advisory Solutions Inc. Sells 18,728 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Bernstein Remains a Hold on Crispr Therapeutics AG (CRSP) - The Globe and Mail
Fox Run Management L.L.C. Acquires New Stake in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors - MSN
What Makes Crispr Therapeutics Ag (CRSP) a Good Buy? - Yahoo Finance
EverSource Wealth Advisors LLC Purchases 84,708 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR-based therapies signal a new direction in tackling infectious diseases - Clinical Trials Arena
CRISPR Therapeutics AG Shows Support at Fibonacci Level2025 Key Highlights & Expert-Curated Trade Recommendations - sundaytimes.kr
Virtu Financial LLC Purchases New Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates - MSN
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns - Yahoo Finance
Benjamin Edwards Inc. Purchases 5,853 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Pattern Scan Adds CRISPR Therapeutics AG to WatchlistPrice Action & Weekly Breakout Stock Alerts - kangso.co.kr
Crispr Therapeutics AG: Stock Surge Amid Clinical Advances - TipRanks
Is CRISPR Therapeutics' (CRSP) Rising Net Loss a Sign of Bold Investment or Growing Pressure? - Yahoo Finance
Crispr Therapeutics shares rise 1.48% premarket after ReproCELL Incorporated receives ¥5.3 million in funding. - AInvest
Equities Analysts Offer Predictions for CRSP Q4 Earnings - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Crispr Therapeutics shares rise 3.12% intraday after Allogene Therapeutics' positive trial updates. - AInvest
Upgrading Crispr Therapeutics To Hold Ahead Of A Catalyst-Rich 2H 2025 - Seeking Alpha
Blair William & Co. IL Cuts Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics Bets Big On Gene-Editing Breakthroughs - Finimize
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by Cetera Investment Advisers - MarketBeat
Crispr Therapeutics Faces Stock Dip Amid Promising Developments - MSN
Crispr Therapeutics shares rise 1.10% premarket after Metagenomi reported positive business updates and financial results. - AInvest
Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings? - Yahoo Finance
Chardan Capital Has Strong Estimate for CRSP FY2026 Earnings - MarketBeat
Westwood Holdings Group Inc. Reduces Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Research Analysts Issue Forecasts for CRSP FY2025 Earnings - MarketBeat
3 Monster Stocks in the Making to Buy Right Now - AOL.com
Barclays Forecasts Strong Price Appreciation for CRISPR Therapeutics (NASDAQ:CRSP) Stock - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Given New $80.00 Price Target at HC Wainwright - MarketBeat
CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading - MSN
Q3 EPS Estimate for CRISPR Therapeutics Boosted by Analyst - MarketBeat
Leerink Partnrs Brokers Reduce Earnings Estimates for CRSP - MarketBeat
CRISPR Therapeutics AG Insider Buying: Douglas Treco Acquires 20,000 Shares - AInvest
CRISPR Therapeutics (NASDAQ:CRSP) Given "Buy" Rating at Chardan Capital - MarketBeat
Crispr Therapeutics Ag (CRSP) 財務データ
収益
当期純利益
現金流量
EPS
Crispr Therapeutics Ag (CRSP) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Treco Douglas A | Director |
Aug 06 '25 |
Buy |
57.03 |
20,000 |
1,140,600 |
22,000 |
| George Simeon | Director |
Jul 16 '25 |
Buy |
52.03 |
989,812 |
51,499,918 |
1,730,179 |
| Patel Naimish | Chief Medical Officer |
May 29 '25 |
Sale |
35.94 |
3,932 |
141,316 |
6,068 |
| Kulkarni Samarth | Chief Executive Officer |
Mar 21 '25 |
Sale |
41.23 |
10,031 |
413,578 |
195,085 |
| Bruno Julianne | Chief Operating Officer |
Mar 21 '25 |
Sale |
41.23 |
1,714 |
70,668 |
10,544 |
| Prasad Raju | Chief Financial Officer |
Mar 21 '25 |
Sale |
41.23 |
2,197 |
90,582 |
16,767 |
| KASINGER JAMES R. | General Counsel and Secretary |
Mar 21 '25 |
Sale |
41.23 |
3,185 |
131,318 |
81,729 |
| Prasad Raju | Chief Financial Officer |
Mar 17 '25 |
Sale |
41.80 |
3,762 |
157,252 |
12,714 |
| Kulkarni Samarth | Chief Executive Officer |
Mar 11 '25 |
Sale |
42.42 |
9,973 |
423,055 |
180,890 |
| Kulkarni Samarth | Chief Executive Officer |
Mar 12 '25 |
Sale |
43.32 |
4,462 |
193,294 |
185,428 |
0.94%
1.72%
大文字化:
|
ボリューム (24 時間):